10-K: Enveric Biosciences Faces Going Concern Doubt Amidst R&D Focus

Enveric Biosciences, a biotechnology company, reported substantial doubt about its ability to continue as a going concern despite recent capital raises, as it focuses on preclinical development of its lead neuroplastogen candidate, EB-003.

Summary

• Enveric Biosciences is a biotechnology company focused on developing next-generation, small-molecule neuroplastogen therapeutics for psychiatric and neurological disorders.
• The company's lead candidate, EB-003 (from the EVM301 Series), is a novel derivative of DMT designed to promote neuroplasticity without hallucinogenic effects, currently advancing through preclinical studies.
• EB-003 aims to selectively engage both 5-HT2A and 5-HT1B receptors for fast-acting, durable antidepressant and anxiolytic effects with outpatient convenience.
• The EVM401 Series was unveiled on February 25, 2025, to broaden the pipeline with additional non-hallucinogenic molecules for addiction and neuropsychiatric disorders, though EB-003 remains the primary focus.
• The company reported an accumulated deficit of $114.8 million as of December 31, 2025, and a net loss of $8.77 million for the year.
• Operating cash outflows for the year ended December 31, 2025, were $8.14 million.
• Cash on hand as of December 31, 2025, was $4.68 million, with working capital of $4.02 million.
• Management and the independent registered public accounting firm have expressed substantial doubt about the company's ability to continue as a going concern due to recurring losses and insufficient cash for future operations.
• The company completed several capital raises in 2025 and early 2026, including an At-the-Market (ATM) offering, warrant inducement transactions, and a registered direct offering, generating approximately $10.5 million in 2025 and an additional $2.6 million in early 2026.
• A 1-for-15 reverse stock split was effected on January 27, 2025, and a 1-for-12 reverse stock split on October 23, 2025.
• The company regained compliance with Nasdaq's minimum bid price and stockholders' equity requirements in late 2025.
• The PsyAI trademark portfolio was evaluated for license or sale in 2025, but no satisfactory offer was received, and it remains an asset.
• The EVM201 portfolio (including EB-002) was out-licensed to MycoMedica Life Sciences, PBC on November 7, 2024, for potential milestone payments up to $62 million and tiered single-digit royalties.
• The company relies on third parties for preclinical studies, clinical trials, and manufacturing of active pharmaceutical ingredients (APIs).
• A material weakness in internal control over financial reporting related to segregation of duties was identified as of December 31, 2025.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing with low sentiment due to the explicit 'going concern' doubt, significant accumulated deficit, and ongoing losses. While recent capital raises provide some liquidity, the fundamental financial challenges and early stage of product development present substantial risks.

Positives

• Successfully raised approximately $10.5 million in net proceeds from equity and warrant transactions during the year ended December 31, 2025.
• Regained compliance with Nasdaq's minimum bid price requirement on November 12, 2025.
• Regained conditional compliance with Nasdaq's stockholders' equity requirement by October 24, 2025, and evidenced compliance upon filing the next periodic report.
• Out-licensed the EVM201 Series program to MycoMedica Life Sciences, PBC, receiving a $20,000 upfront payment and potential for up to $62 million in development and sales milestone payments plus tiered single-digit royalties.
• EB-003 program has completed short-term dose-range finding toxicology studies and is ready to advance into IND-enabling, GLP compliant safety pharmacology, ADMET, and longer-term toxicology studies.
• Unveiled the EVM401 Series to broaden the pipeline with additional non-hallucinogenic molecules targeting addiction and neuropsychiatric disorders.
• Maintains 19 active patent families related to psychedelic-inspired compounds, with 24 issued U.S. patents and 59 pending U.S. and non-U.S. applications.
• Established a scientific advisory board with highly experienced clinical leaders in psychiatry and neuroscience.
• Engaged in a registered direct offering and concurrent private placement in January 2026, raising approximately $1.5 million in gross proceeds.
• Issued 497,200 shares in February 2026 under an ATM agreement for net cash proceeds of $1.3 million.

Negatives

• Incurred an accumulated deficit of $114.8 million as of December 31, 2025, and a net loss of $8.77 million for the year.
• Operating cash outflows were $8.14 million for the year ended December 31, 2025.
• Current cash on hand of $4.68 million is insufficient to satisfy operating cash needs for the 12 months following the filing date, raising substantial doubt about the ability to continue as a going concern.
• Has never been profitable and has no products approved for commercial sale, generating no reportable revenues since inception through December 31, 2025.
• Identified a material weakness in internal control over financial reporting related to insufficient segregation of duties, oversight of work performed, and lack of compensating controls in finance and accounting functions.
• The Facchini Drug License, crucial for research and preclinical studies on psychedelic compounds, expired on December 31, 2025, and its renewal is pending, posing a material adverse effect risk if not renewed.
• The Lincoln Park Equity Line expired on January 1, 2026, and its use was restricted for one year from February 3, 2025, due to a public offering.
• The PsyAI trademark portfolio did not receive a satisfactory offer for license or sale during the RFP period, indicating a lack of immediate strategic value maximization.
• Consolidated employee base to save capital, resulting in only five full-time and one part-time employee, increasing dependence on key personnel and external consultants.
• The company's common stock could be delisted from The Nasdaq Capital Market if it fails to comply with continued listing standards in the future.

Risks

• Ability to continue as a going concern is uncertain without additional capital.
• Dependence on the success of early-stage product candidates (EB-003, EVM401 Series) which may not reach regulatory approval or commercialization.
• Potential difficulties and delays in advancing early research programs through preclinical development and IND application filings into clinical development.
• Catastrophic events (natural disasters, pandemics, cybersecurity incidents, geopolitical conflict) could disrupt business and product development plans.
• Competitors' use of Artificial Intelligence (AI) could lead to countervailing discoveries undermining the current pipeline or create security risks.
• Significant and increasing liquidity needs and potential requirements for additional funding, which may not be available on favorable terms or at all.
• Dependence on key personnel, with a small employee base, making the company vulnerable to their loss.
• Limited study on psychedelic-inspired drug candidates, with future clinical research potentially disputing current understanding of medical benefits, viability, safety, and efficacy.
• Limited resources have led to focus on a particular product candidate, potentially missing more profitable or successful opportunities.
• Intense competition from companies with greater resources and experience in the pharmaceutical industry.
• Preclinical and clinical studies may be conducted outside the U.S., and FDA may not accept data from such studies.
• Clinical trials are expensive, time-consuming, uncertain, and susceptible to delays, termination, or differing interpretations of results.
• Inability to establish efficacy or safety of potential products in preclinical or clinical trials.
• Inability to obtain appropriate governmental approvals to market potential products.
• Inability to manufacture product candidates on a commercial scale or in collaborations with third parties.
• The psychedelic-inspired medicines industry and market are relatively new and may not succeed in the long term.
• Never been profitable, no products approved for commercial sale, and no revenue generated to date.
• Regulatory approval is limited to specific indications, and promotion of unapproved uses could lead to fines or injunctions.
• Business interruptions (e.g., loss of stored materials, facilities) could delay product development.
• Risk of employee misconduct, including noncompliance with regulatory standards and legal requirements.
• Proprietary information or that of customers/partners may be lost or compromised due to security breaches.
• Operating results may vary significantly in future periods due to early development stage and fluctuating expenses.
• Significant ongoing costs and obligations related to research, development, infrastructure, and regulatory compliance.
• Reliance on third parties to plan and conduct preclinical studies and clinical trials, with risks of disputes, delays, or non-compliance.
• Reliance on third-party contract manufacturers for APIs and drug products, with limited control over their performance and compliance.
• Termination or non-renewal of key licenses and agreements, such as the Facchini Drug License, could materially affect operations.
• Negative results from clinical trials or studies by others, or adverse safety events involving similar compounds, could affect share price and financing.
• Use of raw materials requiring regulatory approval, with risks of delays or abandonment of research programs if approvals are not granted.
• Possible increase in costs due to regulatory authorities requiring additional studies or classifying drug candidates as controlled substances.
• Lack of licensing, marketing, or distribution experience, requiring significant resource investment or reliance on third parties with limited control.
• Substantial costs from litigation or other proceedings relating to patent and intellectual property rights.
• Changes in patent law and its interpretation could diminish the value of patents.
• Failure to manage growth effectively as the company expands personnel and partnerships.
• Insurance may not cover all potential risks and hazards, leading to substantial uninsured liabilities.
• Litigation could adversely affect business, financial position, and divert management attention.
• Conflicts of interest due to directors and officers holding positions in other companies.
• Public controversy and negative perception regarding psychedelic-inspired drug candidates could hinder market acceptance.
• Difficulty in quantifying the psychedelic-inspired medicine industry, requiring reliance on own estimates of market data accuracy.
• Rapid growth and increased competition in the psychedelic-inspired medicine and biotechnology industries.
• Changes in legislation, regulations, and guidelines could adversely affect operations and competitive position.
• Management will be required to devote substantial time to comply with public company regulations, increasing costs.
• Tax risks, including potential challenges by taxation authorities to tax filing positions.
• Inability to adequately prevent disclosure of trade secrets and other proprietary information.
• Inability to protect intellectual property rights effectively outside of the United States.
• Common stock could be delisted from Nasdaq.
• Market price of common stock may be subject to significant fluctuations and volatility.
• Future issuance of additional equity securities may result in dilution to existing investors.
• Certain stockholders could attempt to influence changes within the company.
• If securities analysts do not publish research or publish negative evaluations, the stock price could decline.
• Anti-takeover provisions under Delaware corporate law may deter or delay third parties from acquiring the company.
• No anticipation of paying cash dividends in the foreseeable future.
• May not be able to maintain an active trading market for common stock.
• Cash held at financial institutions may exceed federally insured limits, posing a risk of loss.
• Acquisitions or strategic alliances may not realize expected benefits or synergies.

Future Outlook

The company intends to advance its lead candidate, EB-003, through IND-enabling preclinical studies with the aim of initiating first-in-human studies to assess safety, tolerability, and non-hallucinogenic properties, followed by clinical trials for depression or other neuropsychiatric disorders. It plans to submit IND applications and eventually New Drug Applications (NDAs) to the FDA and other regulatory agencies. The company also intends to pursue development of the EVM401 Series to broaden its pipeline, while maintaining primary focus on EB-003. Future capital requirements are significant, and the company expects to fund operations through additional financing arrangements, collaborations, and disciplined cash spending.

Management Comments

• Management believes that EB-003 is the first known compound to selectively engage both 5-HT2A and 5-HT1B receptors with the potential to deliver fast-acting, durable antidepressant and anxiolytic effects with outpatient convenience.
• Management believes that the lead program, the EVM301 Series, and its lead drug candidate, EB-003, are intended to offer a first-in-class, new approach to the treatment of difficult-to-address mental health disorders, mediated by the promotion of neuroplasticity and without also inducing hallucinations in the patient.
• Management intends to assemble a team of clinical experts and principal investigators with experience across multiple mental health and central nervous system indications to be responsible for the management, monitoring, and integrity of the clinical research.
• Management plans to submit filings including Investigational New Drug (IND) applications and, eventually, new drug applications (NDAs) to seek approval with the U.S. Food and Drug Administration (FDA) and with responsible regulatory agencies in other jurisdictions, in connection with product candidates.
• Management believes that if the company continues to pursue the development of MagicMed's proprietary library, the Psybrary, it will help identify and develop the right drug candidates needed to address mental health challenges, including depression, anxiety, and addiction disorders.
• Management intends to both continue to internally develop new drug candidates with associated intellectual property and to acquire, through in-licensing, additional intellectual property from pharmaceutical and biotechnology companies and research institutions.
• Management believes that the licensed-in cannabinoid conjugates have the potential for efficacy that will differentiate their performance against target diseases over simple combination therapies of drugs and cannabinoids.
• Management intends to combine innovative scientific discoveries and bio-chemical synthesis, along with accelerated clinical development plans to create, develop and progress novel therapies using psychedelic-inspired medications and similar compounds.
• Management believes that while scientific knowledge and technology and development experience provide competitive advantages, the company faces potential competition from many different sources.
• Management believes that if the company fails to comply with applicable foreign regulatory requirements, it may be subject to, among other things, fines, suspension of clinical trials, suspension or withdrawal of regulatory approvals, product recalls, seizure of products, operating restrictions and criminal prosecution.
• Management believes that the company has good relationships with its employees.

Industry Context

StockSavvy.ai notes that Enveric Biosciences operates in the nascent but rapidly evolving psychedelic-inspired therapeutics space, aiming to differentiate itself by developing non-hallucinogenic neuroplastogens. This approach seeks to overcome regulatory and public perception challenges associated with classic psychedelics, positioning the company to address significant unmet needs in psychiatric and neurological disorders. The out-licensing of the EVM201 series to MycoMedica Life Sciences reflects a strategic focus on its lead candidate EB-003, a common strategy for early-stage biotech companies to conserve capital and de-risk their pipeline. The industry is characterized by intense competition from major pharmaceutical and biotechnology companies, as well as academic institutions, all vying for breakthroughs in mental health treatments.

Comparison to Industry Standards

• Enveric's focus on non-hallucinogenic neuroplastogens like EB-003 (a DMT derivative) aims to differentiate it from companies developing classic psychedelics (e.g., psilocybin, MDMA) which face stricter Schedule I controlled substance regulations and public perception challenges. Companies like Compass Pathways (COMP) and MindMed (MNMD) are advancing psilocybin and LSD-derived therapies, respectively, often requiring controlled clinical settings due to hallucinogenic effects. Enveric's outpatient convenience goal for EB-003, if achieved, would be a significant competitive advantage over these models.
• The out-licensing of the EVM201 series to MycoMedica Life Sciences, PBC, for potential milestone payments and royalties, is a standard biotech strategy to monetize non-core assets and fund lead programs. This is comparable to how larger pharmaceutical companies often acquire or license promising early-stage assets from smaller biotechs.
• The company's accumulated deficit of $114.8 million and recurring losses are typical for pre-revenue biotechnology companies in the drug discovery and development phase, where substantial R&D investment precedes potential commercialization. This financial profile is common among peers in early-stage clinical development, such as Atai Life Sciences (ATAI) or Cybin (CYBN), which also report significant R&D expenses and net losses as they advance their pipelines.
• The reliance on a scientific advisory board with prominent experts like Maurizio Fava, Stephen M. Stahl, and John Krystal aligns with industry best practices for drug development, leveraging external expertise to guide research and clinical strategy, similar to how many established and emerging biopharma companies structure their scientific guidance.

Corporate Governance

Legal Proceedings

• The company may periodically be involved in legal proceedings, legal actions, and claims arising in the ordinary course of business, but management believes no pending litigation will have a material adverse effect on financial position, results of operations, or cash flows.

Related Party Transactions

• As of December 31, 2025, current liabilities included $99,875 due to related parties, primarily for board compensation payments.
• Board member Sheila DeWitt provided research and development services as an advisory consultant, incurring $3,250 in service fees during 2025, which have been paid.

Stakeholder Impact

• **Shareholders:** Face substantial dilution risk from ongoing and future equity raises, and potential loss of investment if the company cannot continue as a going concern. The market price of common stock is subject to significant volatility.
• **Employees:** The employee base has been consolidated to save capital, increasing dependence on a small number of key personnel. The company believes it has good relationships with its employees.
• **Customers/Patients:** Potential for new non-hallucinogenic neuroplastogen therapeutics for psychiatric and neurological disorders, but success is uncertain and dependent on lengthy and costly clinical trials and regulatory approvals.
• **Creditors:** Face risk due to the company's recurring losses and substantial doubt about its ability to continue as a going concern, which could impact its ability to meet obligations.
• **Regulatory Bodies:** The company is subject to extensive regulation by FDA, DEA, and international authorities, with non-compliance potentially leading to fines, sanctions, or delays in product development.

Next Steps

• Advance EB-003 into IND-enabling, GLP compliant safety pharmacology, ADMET, and longer-term toxicology studies.
• Initiate first-in-human studies for EB-003 to assess safety, tolerability, and non-hallucinogenic properties.
• Conduct clinical trials targeting the treatment of depression or other neuropsychiatric disorders for EB-003.
• Submit Investigational New Drug (IND) applications and eventually New Drug Applications (NDAs) to the FDA and other regulatory agencies.
• Assemble a team of clinical experts and principal investigators for clinical research management.
• Pursue development of the EVM401 Series to broaden the pipeline.
• Continue to internally develop new drug candidates and acquire additional intellectual property through in-licensing.
• Remediate the identified material weakness in internal control over financial reporting, including engaging third-party consultants and implementing improved controls.
• Seek additional working capital through public or private equity or debt financings or other sources.
• Evaluate the PsyAI trademark portfolio for future strategic options after no satisfactory offer was received during the RFP period.
• Obtain renewal of the Facchini Drug License to continue research and preclinical studies on psychedelic compounds.

Key Dates

Recommendation

The explicit 'substantial doubt about our ability to continue as a going concern' from both management and auditors is a critical red flag. Despite recent capital raises, the company's cash position is insufficient for the next 12 months, indicating a high likelihood of further dilutive financing. The company is pre-revenue, has a significant accumulated deficit, and its lead product is still in preclinical stages, meaning commercialization is years away and highly uncertain. The identified material weakness in internal controls adds to operational risk. While the therapeutic area is promising, the financial instability and early development stage make this a high-risk investment with a strong potential for further capital erosion.

Keywords

Neuroplastogen, Psychedelic-inspired therapeutics, EB-003, DMT derivative, Mental health disorders, Depression treatment, Anxiety treatment, Neuropsychiatric disorders, Biotechnology, Drug discovery, Preclinical development, IND filing, FDA approval, Capital raise, Nasdaq compliance, Intellectual property, Warrants, Reverse stock split, Going concern, EVM301 Series, EVM401 Series, MycoMedica Life Sciences, Cannabinoid conjugates, Akos Biosciences